Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review

SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.

Saved in:
Bibliographic Details
Main Authors: Hayıroğlu,Mert İlker, Çınar,Tufan, Tekkeşin,Ahmet İlker
Format: Digital revista
Language:English
Published: Associação Médica Brasileira 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0104-42302020000600842
record_format ojs
spelling oai:scielo:S0104-423020200006008422020-07-17Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature reviewHayıroğlu,Mert İlkerÇınar,TufanTekkeşin,Ahmet İlker Coronavirus Infections Anticoagulants Disseminated intravascular coagulation Fibrin fibrinogen degradation products Blood Coagulation SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.info:eu-repo/semantics/openAccessAssociação Médica BrasileiraRevista da Associação Médica Brasileira v.66 n.6 20202020-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842en10.1590/1806-9282.66.6.842
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Hayıroğlu,Mert İlker
Çınar,Tufan
Tekkeşin,Ahmet İlker
spellingShingle Hayıroğlu,Mert İlker
Çınar,Tufan
Tekkeşin,Ahmet İlker
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
author_facet Hayıroğlu,Mert İlker
Çınar,Tufan
Tekkeşin,Ahmet İlker
author_sort Hayıroğlu,Mert İlker
title Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
title_short Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
title_full Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
title_fullStr Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
title_full_unstemmed Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
title_sort fibrinogen and d-dimer variances and anticoagulation recommendations in covid-19: current literature review
description SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.
publisher Associação Médica Brasileira
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842
work_keys_str_mv AT hayıroglumertilker fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview
AT cınartufan fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview
AT tekkesinahmetilker fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview
_version_ 1756410068771799040